The Motley Fool··Eric VolkmanEli Lilly Surges on FDA Approval of Foundayo, Challenging Novo Nordisk's Weight-Loss Dominance
Eli Lilly stock surged 4% after FDA approval of Foundayo, its oral weight-loss pill priced at $149/month, competing with Novo Nordisk's Wegovy.
LLYNVOFDA approvalstock performance